”1st May 2023KAZIA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
Dr John Friend appointed Chief Executive Officer, succeeding Dr James GarnerSydney, 1st May 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that Chief Executive Officer and Managing Director, Dr James Garner, has resigned from the company.
Dr John Friend, Chief Medical Officer of Kazia, will immediately assume the role of Chief Executive Officer, and will in due course join the Board as Managing Director.Non-Executive Chairman of Kazia, Iain Ross, commented:“Dr James Garner joined Kazia in February 2016 and was responsible for the transformation of the legacy Novogen business into the current organization. He drove the in-licensing of paxalisib and EVT801 and managed the deployment of a broad clinical program for both assets, in collaboration with leading cancer centres in the United States and Europe. He leaves to pursue other opportunities.”
Kazia went to $1.90 before the drug failed . Now trading at 18c
Expand
